Acute-Phase Proteins and Inflammation: Immunological and Clinical Implications

Measuring Immunity: Basic Biology and Clinical Assessment

Volumn , Issue , 2005, Pages 131-143

  Liu, Chau Ching ^a   Ahearn, Joseph M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862976238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012455900-4/50272-5     Document Type: Chapter

References (102)

1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
2. Aldo-Benson M.A., Benson M.D. SAA suppression of immune response in vitro: evidence for an effect on T cell-macrophage interaction. J Immunol 1982, 128:2390-2392.
3. Andrade F., Casciola-Rosen L., Rosen A. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000, 26:215-217.
4. Badolato R., Wang J.M., Murphy W.J., et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203-209.
5. Banka C.L., Yuan T., de Beer M.C., Kindy M., Curtiss L.K., de Beer F.C. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995, 36:1058-1065.
6. Barna B.P., James K., Deodhar S.D. Activation of human monocyte tumoricidal activity by C-reactive protein. Cancer Res 1997, 47:3959-3963.
7. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994, 15:74-80.
8. Benditt E.P., Eriksen N. Amyloid. 3. A protein related to the subunit structure of human amyloid fibrils. Proc Natl Acad Sci USA 1966, 55:308-316.
9. Benditt E.P., Eriksen N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci USA 1977, 74:4025-4028.
10. Benson M.D., Aldo-Benson M.A. SAA suppression of in vitro antibody response. Ann NY Acad Sci 1982, 389:121-125.
11. Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in 'active' coronary artery disease. Am J Cardiol 1990, 65:168-172.
12. Berman S., Gewurz H., Mold C. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol 1986, 136:1354-1359.
13. Besedovsky H., del Rey A., Sorkin E., Dinarello C.A. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986, 233:652-654.
14. Bharadwaj D., Stein M.P., Volzer M., Mold C., Du Clos T.W. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 1999, 190:585-590.
15. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94:874-877.
16. Campos S.P., Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acutephase plasma protein genes. Mol Cell Biol 1992, 12:1789-1797.
17. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., de Beer F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986, 261:9644-9651.
18. Colley C.M., Fleck A., Goode A.W., Muller B.R., Myers M.A. Early time course of the acute phase protein response in man. J Clin Pathol 1983, 36:203-207.
19. de Beer F.C., Hind C.R., Fox K.M., Allan R.M., Maseri A., Pepys M.B. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982, 47:239-243.
20. Dinarello C.A., Cannon J.G., Wolff S.M. New concepts on the pathogenesis of fever. Rev Infect Dis 1988, 10:168-189.
21. Du Clos T.W., Zlock L.T., Rubin R.L. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol 1988, 141:4266-4270.
22. Fahraeus R. The suspension-stability of the blood. Acta Med Scand 1921, 55:1-288.
23. Ferreiros E.R., Boissonnet C.P., Pizarro R., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999, 100:1958-1963.
24. Fu T., Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 2002, 366:195-201.
25. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
26. Galve-de Rochemonteix B., Wiktorowicz K., Kushner I., Dayer J.M. C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. J Leukoc Biol 1993, 53:439-445.
27. Ganapathi M.K., Rzewnicki D., Samols D., Jiang S.L., Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991, 147:1261-1265.
28. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987, 84:7251-7255.
29. Gershov D., Kim S., Brot N., Elkon K.B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192:1353-1364.
30. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1740.
31. Gronroos J.m., Gronroos P. Leucocyte count and C-reactive protein in the diagnosis of acute appendicitis. Br J Surg 1999, 86:501-504.
32. Harris T.B., Ferrucci L., Tracy R.P. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
33. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462-466.
34. Hoffman J.S., Benditt E.P. Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density lipoprotein in primary mouse hepatocyte culture. J Biol Chem 1982, 257:10518-10522.
35. Jiang S.L., Lozanski G., Samols D., Kushner I. Induction of human serum amyloid A in Hep 3B cells by IL-6 and IL-1 beta involves both transcriptional and posttranscriptional mechanisms. J Immunol 1995, 154:825-831.
36. Jones S.A., Novick D., Horiuchi S., Yamamoto N., Szalai A.J., Fuller G.M. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999, 189:599-604.
37. Kaplan M.H., Volanakis J.E. Interaction of C-reactive protein complexes with the complement system I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974, 112:2135-2147.
38. Kapyaho K., Welin M.G., Tanner P., Karkkainen T., Weber T. Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest 1989, 49:389-393.
39. Kisilevsky R., Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1992, 66:778-785.
40. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
41. Kopf M., Baumann H., Freer G., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
42. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144:537-547.
43. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991, 34:1065-1068.
44. Lagrand W.K., Niessen H.W., Wolbink G.J., et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997, 95:97-103.
45. Ledue T.B., Weiner D.L., Sipe J.D., Poulin S.E., Collins M.F., Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998, 35(Pt 6):745-753.
46. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
47. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000, 343:1139-1147.
48. Linke R.P., Bock V., Valet G., Rothe G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem Biophys Res Commun 1991, 176:1100-1105.
49. Liu C.-C., Navratil J.S., Sabatine J.M., Ahearn J.M. Apoptosis, Complement, and SLE: A mechanistic view. Curr Dir of Autoimmun 2003, 7:49-86.
50. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid, a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
51. Macintyre S.S., Kushner I., Samols D. Secretion of C-reactive protein becomes more efficient during the course of the acute phase response. J Biol Chem 1985, 260:4169-4173.
52. Mackiewicz A., Ganapathi M.K., Schultz D., et al. Transforming growth factor beta 1 regulates production of acute-phase proteins. Proc Natl Acad Sci USA 1990, 87:1491-1495.
53. MacLeod C.M., Avery O.T. The occurrence during acute infections of a protein not normally present in the blood. III. Immunological properties of the C-reactive protein and its differentiation from normal blood proteins. J Exp Med 1941, 85:491-498.
54. Malle E., Steinmetz A., Raynes J.G. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993, 102:131-146.
55. Marnell L.L., Mold C., Volzer M.A., Burlingame R.W., Du Clos T.W. C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol 1995, 155:2185-2193.
56. Meek R.L., Benditt E.P. Amyloid A gene family expression in different mouse tissues. J Exp Med 1986, 164:2006-2017.
57. Meek R.L., Urieli-Shoval S., Benditt E.P. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA 1994, 91:3186-3190.
58. Migita K., Kawabe Y., Tominaga M., Origuchi T., Aoyagi T., Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1998, 78:535-539.
59. Miller P.R., Munn D.D., Meredith J.W., Chang M.C. Systemic inflammatory response syndrome in the trauma intensive care unit: who is infected?. J Trauma 1999, 47:1004-1008.
60. Mold C., Gewurz H., Du Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42:23-30.
61. Mold C., Kingzette M., Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol 1984, 133:882-885.
62. Morley J.J., Kushner I. Serum C-reactive protein levels in disease. Ann NY Acad Sci 1982, 389:406-418.
63. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31:1460-1465.
64. Mustard R.A., Bohnen M., Haseeb S., Kasina R. C-reactive protein levels predict postoperative septic complications. Arch Surg 1987, 122:69-73.
65. Nakagomi A., Freedman S.B., Geczy C.L. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000, 101:1785-1791.
66. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T., Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531-2534.
67. Patel H., Fellowes R., Coade S., Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol 1998, 48:410-418.
68. Pepys M.B., Booth S.E., Tennent G.A., Butler P.J., Williams D.G. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994, 97:152-157.
69. Pepys M.B., Lanham J.G., de Beer F.C. C-reactive protein in SLE. Clin Rheum Dis 1982, 8:91-103.
70. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann Intern Med 1999, 130:933-937.
71. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
72. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
73. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97:425-428.
74. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
75. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
76. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
77. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001, 47:403-411.
78. Robey F.A., Jones K.D., Tanaka T., Liu T.Y. Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem 1984, 259:7311-7316.
79. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
80. Saadeh C. The erythrocyte sedimentation rate: old and new clinical applications. South Med J 1998, 91:220-225.
81. Sox H.C., Liang M.H. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986, 104:515-523.
82. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein serum amyloid P component and serum amyloid A protein. Immunol Today 1994, 15:81-88.
83. Steinmetz A., Hocke G., Saile R., Puchois P., Fruchart J.C. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989, 1006:173-178.
84. Strachan A.F., Noakes T.D., Kotzenberg G., Nel A.E., de Beer F.C. C reactive protein concentrations during long distance running. Br Med J (Clin Res Ed) 1984, 289:1249-1251.
85. Su S.B., Gong W., Gao J.L., et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999, 189:395-402.
86. Taga T., Kishimoto T. Gp 130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
87. Tillett W.S., Francis T. Serological reactions in pneumonia with non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
88. Torzewski J., Torzewski M., Bowyer D.E., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18:1386-1392.
89. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:2094-2099.
90. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997, 96:4204-4210.
91. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997, 17:1121-1127.
92. Uhlar C.M., Burgess C.J., Sharp P.M., Whitehead A.S. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 1994, 19:228-235.
93. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
94. Urieli-Shoval S., Linke R.P., Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000, 7:64-69.
95. Volanakis J.E. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982, 389:235-250.
96. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001, 38:189-197.
97. Wilkins J., Gallimore J.R., Moore E.G., Pepys M.B. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998, 44:1358-1361.
98. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999, 37:381-388.
99. Zheng H., Fletcher D., Kozak W., et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995, 3:9-19.
100. Zimlichman S., Danon A., Nathan I., Mozes G., Shainkin-Kestenbaum R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J Lab Clin Med 1990, 116:180-186.
101. Zimmerman M.A., Selzman C.H., Cothren C., Sorensen A.C., Raeburn C.D., Harken A.H. Diagnostic implications of C-reactive protein. Arch Surg 2003, 138:220-224.
102. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.